PubMed · 14746510
Progress in antisense technology.
Abstract
Antisense technology exploits oligonucleotide analogs to bind to target RNAs via Watson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradation of the target RNA. Antisense agents can also alter splicing. During the past decade, much has been learned about the basic mechanisms of antisense, the medicinal chemistry, and the pharmacologic, pharmacokinetic, and toxicologic properties of antisense molecules. Antisense technology has proven valuable in gene functionalization and target validation. With one drug marketed, Vitravenetm, and approximately 20 antisense drugs in clinical development, it appears that antisense drugs may prove important in the treatment of a wide range of diseases.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Stanley T Crooke. 2004. Progress in antisense technology.. https://doi.org/10.1146/annurev.med.55.091902.104408
Cite the original work for its findings. Save a collection to share your selection of sources.